drugset
drugset / Trial / NCT03785054

Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242

NCT03785054 ↗

Phase 1 Completed 71 enrolled Nxera Pharma UK Limited Covance · collab
RandomizedSequentialDouble-blindBasic science

Summary

This is the first time HTL0014242 will be administered to humans. The principal aim of this study is to obtain safety and tolerability data when HTL0014242 is administered orally as single doses to healthy subjects. This information, together with the pharmacokinetics data, will help establish the doses and dosing regimen suitable for future studies in patients

Timeline

Start
2018-11-14
Primary completion
2021-03-11
Completion
2021-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject HTL0014242 Small molecule 1 mg —

Indications

No indication recorded.